{{Drugbox
| IUPAC_name        = ({[(2,3-Dihydroxy-7-nitro-5-quinoxalinyl)methyl]amino}methyl)phosphonic acid
| image             = Becampanel.svg
| CAS_number        = 188696-80-2
| ATC_prefix        = None
| ATC_suffix        = 
| PubChem           = 5491960
| DrugBank          = 
| ChemSpiderID      = 4590791
| chemical_formula =
| C=10 | H=11 | N=4 | O=7 | P=1
| molecular_weight  = 330.191 g/mol
| smiles            = c1c(cc2c(c1CNCP(=O)(O)O)[nH]c(=O)c(=O)[nH]2)[N+](=O)[O-]
| StdInChI          = 1S/C10H11N4O7P/c15-9-10(16)13-8-5(3-11-4-22(19,20)21)1-6(14(17)18)2-7(8)12-9/h1-2,11H,3-4H2,(H,12,15)(H,13,16)(H2,19,20,21)
| StdInChIKey       = ABFMMCZFKUIJGQ-UHFFFAOYSA-N
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| elimination_half-life = 
| excretion         = 
| pregnancy_AU      =  <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US      =  <!-- A / B            / C / D / X -->
| pregnancy_category=  
| legal_AU =  <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA =  <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK =  <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US =  <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status      = 
| routes_of_administration = 
}}

'''Becampanel''' ([[International Nonproprietary Name|INN]]) (code name '''AMP397''') is a [[quinoxalinedione]] [[chemical derivative|derivative]] [[drug]] which acts as a [[competitive antagonist]] of the [[AMPA receptor]] ([[IC50|IC<sub>50</sub>]] = 11 nM).<ref name="TaylorTriggle2007">{{cite book|author1=John B. Taylor|author2=D. J. Triggle|title=Comprehensive medicinal chemistry II|url=https://books.google.com/books?id=fIMvAQAAIAAJ|year=2007|publisher=Elsevier|isbn=978-0-08-044513-7|page=290}}</ref><ref name="pmid17874969">{{cite journal |vauthors=Kwan P, Brodie MJ | title = Emerging drugs for epilepsy | journal = Expert Opin Emerg Drugs | volume = 12 | issue = 3 | pages = 407–22 |date=September 2007  | pmid = 17874969 | doi = 10.1517/14728214.12.3.407 | url = http://informahealthcare.com/doi/abs/10.1517/14728214.12.3.407%20}}</ref><ref name="pmid24387310">{{cite journal |vauthors=Citraro R, Aiello R, Franco V, De Sarro G, Russo E | title = Targeting α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors in epilepsy | journal = Expert Opin. Ther. Targets | volume = 18 | issue = 3 | pages = 319–34 |date=March 2014  | pmid = 24387310 | doi = 10.1517/14728222.2014.874416 | url = http://informahealthcare.com/doi/abs/10.1517/14728222.2014.874416}}</ref><ref name="Organization1988">{{cite book|author=World Health Organization|title=International Nonproprietary Names (INN) for Pharmaceutical Substances|url=https://books.google.com/books?id=dcF1nQEACAAJ|year=1988|publisher=W.H.O.}}</ref> It was investigated as an [[anticonvulsant]] for the treatment of [[epilepsy]] by [[Novartis]], and was also looked at as a potential treatment for [[neuropathic pain]] and [[cerebral ischemia]], but never completed [[clinical trial]]s.<ref name="TaylorTriggle2007" /><ref name="pmid17874969" /><ref name="pmid24387310" /><ref name="pmid20603226">{{cite journal |vauthors=Pathan SA, Jain GK, Akhter S, Vohora D, Ahmad FJ, Khar RK | title = Insights into the novel three 'D's of epilepsy treatment: drugs, delivery systems and devices | journal = Drug Discov. Today | volume = 15 | issue = 17-18 | pages = 717–32 |date=September 2010  | pmid = 20603226 | doi = 10.1016/j.drudis.2010.06.014 | url = http://linkinghub.elsevier.com/retrieve/pii/S1359-6446(10)00226-6}}</ref>

==References==
{{Reflist|2}}

{{Anticonvulsants}}
{{Ionotropic glutamate receptor modulators}}

[[Category:AMPA receptor antagonists]]
[[Category:Amines]]
[[Category:Anticonvulsants]]
[[Category:Ketones]]
[[Category:Nitro compounds]]
[[Category:Quinoxalines]]


{{nervous-system-drug-stub}}